07:38 AM EDT, 07/28/2025 (MT Newswires) -- Celcuity ( CELC ) stock was up more than 113% pre-bell Monday after the company said results from a phase 3 trial showed that a combination of gedatolisib, palbociclib, and fulvestrant reduced the risk of disease progression or death by 76% compared with fulvestrant alone in patients with locally advanced or metastatic breast cancer.

Mill City Ventures III ( MCVT ) shares were 61% higher, extending Friday's rally.

TruGolf ( TRUG ) stock was up 22% following a 5.8% loss on Friday.

22nd Century Group ( XXII ) shares were 23% higher, adding to a 4.1% increase in the previous session.